Literature DB >> 15351483

Heparin binding activity of orf virus F1L protein.

A Scagliarini1, L Gallina, F Dal Pozzo, M Battilani, S Ciulli, S Prosperi.   

Abstract

The orf virus is the type species of the Parapoxvirus genus and is the causative agent of contagious echtyma, a debilitating skin disease of sheep and goats, which can also affect man. The virus exhibits a restricted host range, even if it has been shown to bind to a wide range of tissues of non-permissive species. This ability is an argument for its potential use as an expression vector. Since most mammalian cell types express heparan sulfate (HS) surface receptors, we assumed that HS could serve as receptors to mediate orf virus binding. In this study, we showed that orf virus is inhibited by the addition of soluble heparin in cell cultures. Affinity chomatography using heparin agarose demonstrated that orf virus F1L is the major heparin binding protein. Furthermore, the recombinant F1L protein was visualised on the cell surface by confocal microscopy, and rabbits immunised with recombinant F1L protein produced virus neutralising antibodies. These results confirm that the F1L immunodominant protein is also involved in virus binding to cells as for the vaccinia homologue H3L protein. Heparin also inhibited the binding of the F1L protein to cells showing that this protein has a role in the early stages of infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351483     DOI: 10.1016/j.virusres.2004.04.018

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  2 in total

1.  Identification and characterization of monoclonal antibodies against the ORFV059 protein encoded by Orf virus.

Authors:  Hong Li; Zhangyong Ning; Wenbo Hao; Shimeng Zhang; Xiaoqing Liao; Ming Li; Shuhong Luo
Journal:  Virus Genes       Date:  2012-01-12       Impact factor: 2.198

2.  Orf virus DNA vaccines expressing ORFV 011 and ORFV 059 chimeric protein enhances immunogenicity.

Authors:  Kui Zhao; Wenqi He; Wei Gao; Huijun Lu; Tiesuo Han; Jing Li; Ximu Zhang; Bingbing Zhang; Gaili Wang; Gaoli Su; Zhihui Zhao; Deguang Song; Feng Gao
Journal:  Virol J       Date:  2011-12-29       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.